BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Q3 Sales In Line With Estimates
Update: 2025-10-28
Description
BioMarin's latest earnings: Sales are up, but profits take a hit! Discover why the pharma giant's stock remained flat despite revenue growth, as rising costs and lowered earnings guidance disappoint investors. Is this a temporary setback or a sign of deeper challenges for BioMarin? Find out which key products are driving growth and what the future holds for this rare disease treatment leader.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
